AllDocs -> cancers

Prostate Cancer Biomarkers Methods for Diagnosis of Prostate Cancer Intellectual Property ID Number 93 Contact Robert F. Williams, Ph.D., M.B.A. Director, Office of Technology Transfer (757) 446-5099 WilliaRF@evms.edu Inventors George L. Wright, Ph.D. Lisa Cazares B-L Adam Field Oncology Technology Protein biomarkers for prostate cancer diagnostics Key Features • Diagnostic biomarkers with potential for early detection of prostate cancer • Detection formats ranging from immunoassay to mass spectrometry possible Stage of Development Dr. Wright and colleagues have conducted studies on 300 patient samples and shown these potential biomarkers have utility in differentiation ...

Prostate Cancer Biomarkers Methods for Diagnosis of Prostate Cancer Intellectual Property ID Number 117 Contact Robert F. Williams, Ph.D., M.B.A. Director, Office of Technology Transfer (757) 446-5099 WilliaRF@evms.edu Inventors George .L. Wright, Ph.D. Lisa Cazares Field Oncology Technology Protein biomarkers for prostate cancer diagnostics Key Features • Diagnostic biomarkers with potential for early detection of prostate cancer • Detection formats ranging from immunoassay to mass spectrometry possible Stage of Development Dr. Wright and colleagues have conducted studies on patient samples with known histories where laser capture microdissection was used to collect ...

Prostate Cancer Detection Methods for Diagnosis of Prostate Cancer Intellectual Property ID Number 91 Contact Robert F. Williams, Ph.D., M.B.A. Director, Office of Technology Transfer (757) 446-5099 WilliaRF@evms.edu Inventors George L. Wright, Ph.D. Field Oncology Technology Assay for the diagnosis of prostate cancer Key Features • Methodology allowing quantitation of PSMA/PSMA' • Detection formats ranging from immunoassay to mass spectrometry possible Stage of Development Preliminary study of 60 serum samples (24 normal, 10 BPH, 17 PCA and 9 prostatitis) demonstrated that serum levels of PSMA in patients with BPH and prostatitis were below those for the normal males in the study, ...

Obesity, Serum Prostate Specific Antigen and Prostate Size: Implications for Prostate Cancer Detection Stephen J. Freedland,* Elizabeth A. Platz, Joseph C. Presti, Jr., William J. Aronson, Christopher L. Amling, Christopher J. Kane and Martha K. Terris From the Department of Urology, Johns Hopkins School of Medicine (SJF, EAP), Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health (EAP) and Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins Medical Institutions (EAP), Baltimore, Maryland, Department of Urology, Stanford University School of Medicine and Department of Surgery, Veterans Administration Medical Center, Palo Alto (JCP), Department of Surgery, Veterans Administration Greater Los Angeles Healthcare System and Department of Urology, University of California-Los Angeles School of Medicine, Los Angeles (WJA), Department of Urology, San Diego Naval Hospital ...

April, 2005 To: Notre Dame Club of North Florida From: George Fipp, MD (NDSA Club Representative) Re: NDSA’s Prostate Cancer Initiative Dear North Florida Club Member: The Notre Dame Senior Alumni (NDSA) is undertaking a Prostate Cancer initiative program to assist in the fight against this deadly disease. This letter is being sent to ND senior alumni, 55 + years of age to appraise you of this program and ask for your participation. The program is called PACE ( Prostate and Cancer Education) and is an approved program under the direction of the Community Service Department of our Alumni Association. What the Program seeks to do: • AWARENESS. Provide information to club members and at risk individuals in our community on the basic facts of prostate cancer . The focus here is early detection and encouraging men to begin getting tested by their family doctor or an urologist. ...

Prostate Cancer Screening Prostate Cancer This year, up to 30,000 men will die from prostate cancer . It is the second leading cause of cancer deaths in men after lung cancer , especially among older men. The good news is that most prostate cancer is slow grow- ing – only 30 percent of men diagnosed with prostate cancer will die from the disease. Prostate cancer occurs in the prostate gland, which rests below the bladder in males. There are no known ways to prevent prostate cancer . However, here are some screening tests that your physician can perform to screen for the presence of prostate cancer , although these tests pose challenges because of false positive results (abnormal test results when cancer is not present) and false negative results (normal results when cancer is present). In addition, the benefits of current treatment have not been firmly established. Long-term studies to ...

Progenics Pharmaceuticals And Cytogen Create Fully Human Monoclonal Antibodies For Prostate Cancer Therapy Through Collaboration With Abgenix Human monoclonal antibodies are designed to target and destroy prostate cancer cells without affecting surrounding healthy cells. New Orleans, March 27, 2001 – Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) and Cytogen Corporation (Nasdaq: CYTO) have successfully created human monoclonal antibodies, using XenoMouse™ technology from Abgenix, Inc. (Nasdaq: ABGX), that target prostate specific membrane antigen (PSMA), a marker found on prostate cancer cells. The Progenics-Cytogen joint venture, the PSMA Development Company LLC, has entered into a collaboration with Abgenix with to use the company's XenoMouse technology for generating fully human antibodies to PSMA. Terms of the agreement were not disclosed. The scientific findings were announced today by Progenics at the ...

Abgenix Initiates Phase 2 Clinical Trial Of ABX-EGF In Prostate Cancer FREMONT, CA, January 3, 2002 - Abgenix, Inc. (Nasdaq: ABGX) announced today the initiation of a Phase 2 clinical trial of ABX-EGF in patients with prostate cancer . ABX-EGF is a fully human monoclonal antibody specific for the epidermal growth factor receptor (EGFr), a receptor identified in many solid tumor types. This clinical trial, the fourth Phase 2 study of ABX-EGF, is designed to assess the safety and efficacy of ABX-EGF in patients with hormone resistant prostate cancer without metastasis. Abgenix is developing ABX-EGF in collaboration with Immunex Corporation. This multi-center, open-label Phase 2 study will enroll up to 50 patients. Patients will receive intravenous infusions of 2.5 mg/kg of ABX-EGF weekly over an 8-week treatment cycle, for up to 5 cycles. The primary efficacy endpoint of the study will be measured by prostate ...

For more information, on this and other Calgary Health Region news, please refer to our website at www.calgaryhealthregion.ca March 10, 2006 news release New Prostate Cancer Clinic Speeds Up Screening, Diagnosis A new clinic, opened in September by the Prostate Cancer Institute, is significantly reducing the time it takes to confirm a prostate cancer diagnosis. Men have a one in six probability of developing prostate cancer in their lifetimes, making it one of the most commonly diagnosed cancers. The Rapid Access Clinic, the first of its kind in Canada for early prostate cancer detection, provides further screening for the disease, the type of testing that would normally occur over the first few appointments with a urologist. The service also reduces the time it takes patients to see a specialist, a step that can account for up to thirty per cent of a patient’s overall ...

The NCCHTA manages the HTA programme under contract from the Department of Health’s Research and Development Division. web: www.ncchta.org NHSweb: nww.hta.nhsweb.nhs.uk Cancer a Government priority Cancer is a Government priority. Research is a major theme within the National Cancer Plan, which, amongst other things, set out plans for the National Cancer Research Network and the National Cancer Research Institute (NCRI). Within this framework, the NHS Plan is to increase by £1 million the resources devoted to prostate cancer research for each of the subsequent three years. (The NHS Prostate Cancer Programme website has more detail) The DH Portfolio Director for Cancer Research, Dr Russell Hamilton, is ensuring that these increased investments go towards research of greatest benefit to patients. The NHS HTA Programme has been a major contributor towards ...

-more- Media Contact: Cynthia Harding E-mail: Cynthia.Harding@cshs.org Telephone: (310) 423-4768 For release March 20, 2006 POTENTIAL PROSTATE CANCER TREATMENT IMPROVEMENTS DISCOVERED BY RESEARCHERS AT CEDARS-SINAI MEDICAL CENTER Raloxifene, Drug Used For Osteoporosis, Shown To Potentially Benefit Prostate Cancer Patients LOS ANGELES (March 20, 2006) – In a study to be published in the April, 2006 issue of the British Journal of Urology International, researchers at the Louis Warschaw Prostate Cancer Center at the Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center have shown that Raloxifene, a drug commonly used to treat osteoporosis, has a potential clinical benefit in treating men with prostate cancer . This study has implications for the approximately 35,000 men who will die this year of advanced prostate cancer . Prostate ...

xvii PREFACE Prostate cancer is the second leading cause of death in men. Charles Huggins first found that metastatic prostate cancer responds to androgen- ablation therapy, which heralded the beginning of a new era of prostate cancer therapy. Later, Andrew Schally and others showed that advanced prostate cancer responded to the LHRH agonist as decreased serum testosterone level to 25% and marked reduction in cancer -associated bone pain. The discovery of androgen receptor (AR) led to the screening of chemical libraries for AR blockers. Since then, antiandrogens, including flutamide and casodex, have been in continual use as therapeutic agents. Yet, with either androgen ablation via surgical or medical castration, with or without additional combination of various antiandrogens, eventually most of, if not all, prostate cancers still progress into the Hormone Refractory stage and the ...

1 HORMONAL THERAPY FOR PROSTATE CANCER : CLINICAL AND EXPERIMENTAL EVIDENCE Hiroshi Miyamoto and Chawnshang Chang Departments of Pathology & Laboratory Medicine and Urology University of Rochester Medical Center Rochester, New York, USA Introduction The role and mechanism of androgen function have been studied in a variety of androgen target organs, including the prostate . As is the case with normal prostate development, the growth of prostatic neoplasms is generally dependent on androgens, especially on 5 -dihydrotestosterone (DHT). Since 1941 when Huggins and Hodges 1 published their Nobel Prize-winning study on the effects of hormone manipulation in patients with metastatic prostate cancer (PCa), hormonal therapy remains the critical therapeutic option for advanced disease. Multiple strategies have been used to reduce serum levels of ...

13.1. INTRODUCTION AND SUMMARY Prostate cancer was the second commonest non-cutaneous cancer in men (Table 13.1). Men had a 5% risk of developing prostate cancer before age 75, and a 1.6% chance of dying before the same age. Prostate cancer incidence has increased since 1994, at an annual rate of 1.6%. Whether this is due to better case- finding, more incidental diagnoses or a true increase in incidence is unknown. Table 13.1. Summary of incidence and mortality statistics: prostate cancer INCIDENT CASES DEATHS All cancers (invasive, in situ and uncertain) (ICD-O-2 C61) 1997 cases 1133 536 % of all cancers (male) 10.7% 13.3% Incidence and mortality rates (per 100,000 persons per year) crude rate 62.6 29.6 World age-standardised rate 44.6 18.8 European age-standardised rate 71.3 32.9 cumulative risk ...

(more) Media Contact: Cynthia Harding Telephone: 310-423-4768 E-mail: Cynthia.harding@cshs.org PEPPER COMPONENT HOT ENOUGH TO TRIGGER SUICIDE IN PROSTATE CANCER CELLS LOS ANGELES (MARCH 15, 2006) – Capsaicin, the stuff that turns up the heat in jalapeños, not only causes the tongue to burn, it also drives prostate cancer cells to kill themselves, according to studies published in the March 15 issue of Cancer Research. According to a team of researchers from the Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center, in collaboration with colleagues from UCLA, the pepper component caused human prostate cancer cells to undergo programmed cell death or apoptosis. Capsaicin induced approximately 80 percent of prostate cancer cells growing in mice to follow the molecular pathways leading to apoptosis. Prostate cancer tumors treated with capsaicin were ...

COLLÈGE DES MÉDECINS DU QUÉBEC Y OU A RE A M AN , 50-70 Y EARS OF A GE A F EW T HOUGHTS B EFORE H AVING A P ROSTATE C ANCER S CREENING T EST T HE A DVANTAGES AND D ISADVANTAGES Page 2 A screening test for prostate cancer has been avail- able for some years. It is known as “ prostate -specific antigen determination” (or PSA measurement) and involves taking a blood sample. There is some debate at the moment on the real benefits of using this test to detect prostate cancer in men who ...

PROSTATE CANCER 383 CHAPTER 17 Prostate cancer JuddW.Moul, MD , FACS , Kenneth J.Pienta, MD , Brent K.Hollenbeck, MD , and Michael E.Ray, MD , P h D Prostate cancer is the most common cancer in American men. Despite the fact that this cancer will be diagnosed in an estimated 232,090 American men in the year 2005 and will lead to the death of approximately 30,350 men, there is no universally agreed-upon strategic plan for its diagnosis and management. Epidemiology Age The risk of developing prostate cancer begins to increase at age 50 years in white men who have no family history of the disease and at age 40 years in black men and those who have a first-degree relative (father, brother) with prostate cancer . Risk increases with age, ...

Conveniently Located The hospital is located one mile south of Interstate 35 at 39th and Rainbow Boulevard in Kansas City, Kan., and is easily accessible from both sides of the state line. The U n i v ersit y of K ansas H ospital www.kumed.com 3901 Rainbow Blvd. Kansas City, KS 66160 For More Information For more information or to schedule an appointment, please call 913-588-1227 or toll-free 877-332-6048. Or visit our Web site at www.kumed.com . • A team of experts for each patient • The newest treatment options • The benefits of an academic medical center Midwest Prostate Center Care for the Whole Person K a n s s R ve r M is ou ri R iver Missouri Kansas 2/06 BR755 The ...

Prostate Px™: Integrated Molecular Test Can Predict Prostate Cancer Recurrence Yonkers, New York, February 24, 2006 / – Aureon Laboratories announced today that it has launched Prostate Px , a unique predictive test that can provide patients and their physicians with a personalized determination of their risk for prostate cancer recurrence following removal of the prostate . Prostate cancer is the most frequently diagnosed cancer and second leading cause of cancer death among men in the United States with approximately 230,000 newly diagnosed cases in 2005 and nearly 30,000 deaths. About 85% of all cases diagnosed are clinically localized and treated with radical prostatectomy or radiation therapy. Managing these patients is complicated because it is difficult to accurately predict which patients are at high or low risk for developing prostate cancer recurrence post-operatively. ...

PSA Test Increasing Early Detection of Prostate Cancer More than a quarter of a million new cases of prostate cancer are expected to be diagnosed this year, thanks in part to the prostate -specific antigen (PSA) blood test that is now recommended as an early cancer detection test in all men over age 50. "PSA is the most important, accurate and clinically useful biochemical marker in the prostate ," said Pathologist David G. Bostwick, MD. The PSA test, performed in most laboratories across the country, is rapid, virtually painless and, when results are elevated, is a reliable indicator of prostate problems, particularly cancer and specifically prostatic adenocarcinoma. PSA detects a similar group of cancers that are potentially curable, explained Dr. Bostwick, a member of the American Society for Clinical Pathology and Professor and Consultant in the Department of Pathology at Mayo Clinic in ...

1 Pathological distinction of prostate cancer tumors based on DNA microarray data M. Moradi a* , P. Mousavi a and P. Abolmaesoumi a,b a School of Computing, Queen’s University, Kingston, Ontario, Canada K7L 3N6; b Department of Electrical and Computer Engineering, Queen’s University, Kingston, Ontario, Canada K7L 3N6 ABSTRACT Prostate cancer is currently a leading cause of public health concern for developed countries. Prostate tumors are among the most controversial types of cancer in terms of diagnosis and grading. With the advent of high throughput DNA microarrays in the last few years, researchers have used gene expression data for prostate tissue classification. Many of these studies target the detection of cancer by classification of samples in normal and tumor classes. However, treatment planning ...

IMPROVED PREDICTION OF PROSTATE CANCER RECURRENCE BASED ON AN AUTOMATED TISSUE IMAGE ANALYSIS SYSTEM Mikhail Teverovskiy 1 , Vinay Kumar 1 , Junshui Ma 1 , Angeliki Kotsianti 1 , David Verbel 1 , Ali Tabesh 1, 2 , Ho-Yuen Pang 1 , Yevgen Vengrenyuk 1 , Stephen Fogarasi 1 , Olivier Saidi 1 1 Aureon Biosciences Corporation, 28 Wells Ave, Yonkers, NY 10701 2 Department of Electrical and Computer Eng., University of Arizona, Tucson, AZ 85721 ABSTRACT Prostate tissue characteristics play an important role in predicting the recurrence of prostate cancer . Currently, experienced pathologists manually grade these prostate tissues using the Gleason scoring system, a subjective approach which ...

2 nd Annual National Symposium on Prostate Cancer Clark Atlanta University March 30-31, 2006 Thomas W. Cole, Jr., Research Center for Science and Technology Thursday, March 30, 2006 8:00 – 10:30 A.M. RCMI External Advisory Committee Meeting 12:00 Noon – 6:00 P.M. Symposium Registration Lobby, 1 st Floor 12:00 – 4:00 P.M. Pre-Symposium Activities 4:00 – 6:00 P.M. Opening Ceremony Auditorium Mr. Andrew Young Former U.N. Ambassador 6:00 – 8:00 P.M. Reception Exhibition Hall, 2 nd Floor Friday, March 31, 2006 8:00 – 5:00 P.M. Symposium Registration Lobby, 1 st Floor 8:30 – 9:00 A.M. Continental Breakfast Board Room, 1036/1038 9:00 A.M. Plenary Session I Chair Dr. David Cooke ...

1 Request for Proposals Breast Cancer , Prostate Cancer , and Ovarian Cancer Research Awards Georgia Cancer Coalition – www.georgiacancer.org Release Date: Monday, February 6, 2006 Receipt Date: Friday, April 7, 2006 Award Date: Monday, May 22, 2006 1.0 Background The Breast, Prostate , and Ovarian Cancer Research Awards were established during the 2000 session of the Georgia General Assembly. Georgians may contribute to a research fund for breast, prostate , and ovarian cancers on their state income tax returns. Since its inception, Georgian’s have contributed over $1 million to the Fund. This year’s contributions total approximately $368,000 ($343,000 from the citizens of Georgia and $25,000 from the proceeds of the 2005 Tour de Georgia). Contributions are tax-deductible and may also be made directly to the Georgia Cancer Coalition, a Georgia non-profit corporation. ...

Matt Kaser Christina Kang Joey Steininger BE.105 Prostate Cancer : Abstracts Nanocell Application to Prostate Cancer Over 234,000 men in the United States will be diagnosed with prostate cancer this year. It is the second leading cause of cancer -related deaths in men. Current treatments of prostate cancer such as chemotherapy show drastic side effects including hair loss, nausea, vomiting, infertility, and liver damage. Despite these violent symptoms, the chemotherapy drugs do not cure the cancer , but merely prolong or improve the quality of life. Docetaxel is one of two common chemotherapy drugs discovered in 2004. Docetaxel inhibits cell growth by inducing apoptotic cell death through the cleavage of caspase-3. However, docetaxel also affects normal body cells, which is a cause of side effects. This study proposes a new treatment for prostate cancer using the novel ...

COMMON TREATMENT FOR OSTEOPOROSIS MAY HELP MEN WITH PROSTATE CANCER SUFFERING FROM BONE LOSS SAN FRANCISCO , Feb. 25 – Men with prostate cancer who experience bone loss from cancer treatment could benefit from a weekly oral therapy commonly given to women with osteoporosis, according to a study presented by the University of Pittsburgh Medical Center (UPMC) at the American Society of Clinical Oncology Prostate Cancer Symposium, Feb. 24 to 26 at the San Francisco Marriott. The study, abstract number 139, will be featured in a press program at the meeting, 7:30 a.m., Sunday, Feb. 26. “In previous studies, we have determined that men who receive androgen deprivation therapy, a frequently used treatment for prostate cancer , suffer from severe drops in bone mass and are at an increased risk for fracture,” said study principal investigator Susan Greenspan, M.D., professor of medicine, ...

Prostate Cancer Fact Sheet Definition • The prostate is a spherical gland in men about the size of a walnut (the most commonly used example to describe the size of the prostate ), located below the bladder and in front of the rectum. • Its function is to secrete part of the seminal fluid which is essential to sperm life. Contrary to popular belief, a normal prostate plays no role in the control of urine flow. • The three most frequent diseases to occur in the prostate gland are: benign prostatic hyperplasia (a non cancerous enlargement of the glad that can obstruct the urethra and modify or obstruct the flow of urine), prostatitis (infection of the gland) and prostate cancer . • In some men, prostate cancer is a slow-growing disease and can take many years before the disease becomes life threatening without treatment. In others, prostate cancers can grow and spread ...

MEDIA RELEASE 2 March 2005 MORE FUNDING TO FIGHT INCREASE IN PROSTATE CANCER Prostate cancer will be the most common cancer in NSW by 2011, affecting one in three men and accounting for 16 per cent of all cancers diagnosed, according to the Cancer Institute NSW. The Cancer Institute NSW today announced that it will provide $3.75 million to fund one of the most comprehensive prostate cancer research programs ever undertaken in Australia to meet the challenge. A consortium of six NSW research agencies will undertake the research. These include the Prince of Wales, Royal Prince Alfred, Westmead and St Vincent’s Hospitals, along with the Garvan Institute of Medical Research and the CSIRO. “This research will help to develop new prostate cancer screening and treatment processes, and examine the key gene defects linked to prostate cancer ,” Professor Jim Bishop, head of the ...

Prostate Cancer Early Detection Recommendations (Updated 2005) hese recommendations have been developed by the Michigan Cancer Consortium Advisory Committee on Prostate Cancer to help Health Care Providers guide asymptomatic men and their families in making informed decisions about prostate cancer early detection. T Men who MAY be candidates for early detection*: • Prostate cancer is a disease of older men. Early detection beginning at age 50 may be appropriate for men who have a life expectancy of at least 10 years. Seventy percent of prostate cancer incidence is in men older than 65 though prostate cancer in men less than 50 is more likely to be aggressive. • Higher risk men may be candidates for early detection starting at age 45. Men at higher risk are: African Americans have an incidence rate of prostate cancer 1.4 times that of Whites, ...

WHO: Shapiro & Smith Dance WHAT: ANYTOWN “PSA in the USA” campaign to benefit prostate cancer patient services WHERE: Nationwide beginning Fall 2005 Shapiro & Smith’s ANYTOWN to Promote Prostate Cancer Awareness & Patient Support Audiences invited to support prostate cancer patient services MINNEAPOLIS, MN (September 2004) — the “PSA in the U.S.A.” campaign - a partnership between Us Too and the national tour of Danial Shapiro and Joanie Smith’s “ANYTOWN: Stories of America,” was created by Mr. Shapiro who was diagnosed with prostate cancer at age 44 in October 2002. The awareness campaign seeks to reach 1 million men over the course of a 5-7 year national tour of “ANYTOWN” danced to the music of Rock & Roll Hall of Famer Bruce Springsteen , his wife, Patti Scialfa , and E- Streeter Soozie Tyrell – who is Ms. Smith’s sister. Our mission is to ...